Newer Obesity Medications Could Interact With Birth Control Pills

For women grappling with obesity and undergoing treatment with drugs such as semaglutide (known as Ozempic) or tirzepatide (referred to as Mounjaro), the benefits of these medications are remarkable. Belonging to a novel category known as GLP-1 receptor agonists, they offer substantial and rapid weight loss, improved blood sugar management, and an enhanced quality of life. These drugs represent a significant departure from the long-established view that surgical procedures were the most effective long-term solution for obesity.

However, the quest for accelerated weight loss and enhanced blood sugar control carries an unexpected caveat. Many women dealing with obesity, who are also taking oral contraceptives, might be unaware that these medications, particularly Mounjaro, can impede the absorption and efficacy of birth control pills, potentially increasing the risk of unintended pregnancies.

One of the mechanisms through which drugs like Ozempic operate is by delaying the transit of food from the stomach to the small intestine. While research in this area is still evolving, it is theorized that this delay in gastric emptying may influence the absorption of birth control pills. Another hypothesis suggests that vomiting, a common side effect associated with these medications, might also interfere with the contraceptive’s effectiveness. At lower doses, the impact on absorption and gastric emptying may be minimal. However, as the dosage increases, these concerns become more prevalent, sometimes resulting in diarrhea, which is another factor that can disrupt the absorption of any medication.

In the United States, approximately 42% of women are obese, with 40% of them falling between the ages of 20 and 39. While these new drugs hold the potential to improve fertility outcomes for obese women, particularly those with polycystic ovary syndrome (PCOS), only one drug, Mounjaro, currently carries a warning about its potential impact on birth control pill efficacy. Regrettably, it appears that some healthcare providers may not be fully informed about or may not be advising their patients regarding this risk. Furthermore, the data remains inconclusive regarding whether other drugs in the same class, like Ozempic, pose similar risks.

For patients seeking to safeguard themselves from unplanned pregnancies, it is advisable to use condoms when commencing treatment with GLP receptor agonists. While the effect on gastric emptying is generally minimal at lower doses, it becomes more significant with higher dosages or the onset of diarrhea. While this aspect was not a conventional subject of discussion, it is now recommended that patients consider adding a barrier contraceptive method such as a condom, at least four weeks before initiating their initial dose or when adjusting the dosage. Additionally, it is advisable to schedule the GLP receptor agonist injection at least one hour apart from any other medication, including oral contraceptives.


The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your health care provider first. Full Disclaimer

COVID-19 mRNA Pregnancy

Share this post